tirzepatide osa Sleep Apnea and Obesity: Risks, Policy, and (Zepbound®) tirzepatide for the treatment of

Transl Psychiatry 8, 242 (2018)

In addition to not being a non-randomized controlled trial, criticisms of the study include that the published data was not sufficient to establish a causal association between GLP-1 receptor agonist use and NAION

This is expected and does not necessarily indicate a problem, but monitoring during the transition is important

Severe, persistent vomiting that prevents adequate fluid intake, intense abdominal pain, or signs of gastroparesis (severe gastric retention) warrant medical evaluation

Side effects are one reason, but cost, access, expectations, other health changes, and personal preference can also matter